Effect of Gabapentin-Fluoxetine Derivative GBP1F in a Murine Model of Depression, Anxiety and Cognition
Aneela Gohar,Gowhar Ali,Umer Rashid,Khalid Rauf,Mehreen Arif,Muhammad Sona Khan,Yasser MSA Alkahramaan,Robert DE Sewell
DOI: https://doi.org/10.2147/DDDT.S407229
2023-06-16
Abstract:Aneela Gohar, 1 Gowhar Ali, 2 Umer Rashid, 3 Khalid Rauf, 1 Mehreen Arif, 1 Muhammad Sona Khan, 1 Yasser MSA Alkahramaan, 1 Robert DE Sewell 4 1 Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, Pakistan; 2 Department of Pharmacy, University of Peshawar, Peshawar, Pakistan; 3 Department of Chemistry, COMSATS University Islamabad Abbottabad Campus, Abbottabad, Pakistan; 4 Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK Correspondence: Khalid Rauf, Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, Khyber Pakhtoonkhwa, 22060, Pakistan, Email Background and Objective: Gabapentin is a commonly prescribed antiepileptic agent for seizures, which is also used for pain and addiction management. Due to growing evidence of its abuse liability, there has been an incentive to synthesise potentially useful gabapentin derivatives devoid of adverse effects. A gabapentin adduct with a fluoxetine moiety, GBP1F, was assessed for any sedative, cognitive, anxiolytic, or antidepressant-like actions in murine behavioral models. Materials and Methods: Selected groups of mice were used for each behavioral paradigm, and the effect of GBP1F (5, 10, and 15 mg/kg) was assessed using spontaneous locomotor activity, the tail suspension test, elevated plus maze test, and the Y maze test models. Immediately following behavioral experiments, postmortem striatal and hippocampal tissues were evaluated for the effect of GBP1F on concentrations of dopamine, DOPAC, HVA, serotonin, 5-HIAA, vitamin C, and noradrenaline using high performance liquid chromatography with electrochemical detection. Results: GBP1F induced a mild suppression of locomotor activity, ameliorated anxiety and depression-like behavior, did not alter cognitive behavior, and raised serotonin and 5-HIAA concentrations in the hippocampus and striatum. GBP1F also positively enhanced dopamine and vitamin C tissue levels in the striatum. Thus, GBP1F represents a compound with anxiolytic- and antidepressant-like effects though further studies are warranted at the molecular level to focus on the precise mechanism(s) of action. Keywords: depression, anxiety, DOPAC, HVA, 5-HIAA, gabapentin, cognition Gabapentin is a clinically used anticonvulsant with broad utility in the management of neuropathic pain, anxiety, alcohol withdrawal, and bipolar disorders. 1,2 It exerts pharmacological activity mediated via interactions with molecular targets located within the CNS. These include the auxiliary α2δ subunit of voltage-gated calcium channels, inhibition of inward rectifying potassium channels, 3 nitric oxide signaling, 4 and serotonergic pathways. 3 Gabapentin has been reported to decrease immobility time in animal models of depression through modulation of serotonergic, nitrergic and inward rectifying potassium channels. 5 It has also been documented to enhance blood serotonin levels in healthy volunteers. 6 Despite its clinical approval and off-label use in diverse populations, there has been increased prescribing of gabapentin globally, and over the last two decades there is emerging evidence of gabapentin misuse, abuse and dependence. 5,7–9 Due to its safety, tolerability and abuse liability profile, there has been an incentive to synthesise potentially useful gabapentin derivatives by addition of diverse chemical moieties such as thiols, 10 Schiff bases, 11 salicylaldehyde 12 and sulfonamides. 13 These derivatives have been evaluated for their possible application as antioxidants, anticancer agents, anticonvulsants and also against neuropathic pain. 14 Acknowledging the promise of positive outcomes associated with the addition of pharmacologically and chemically diverse moieties to gabapentin, this study was designed to explore the potential of a new gabapentin adduct with fluoxetine (GBP1F; Figure 1) for any possible sedative, anxiolytic or antidepressant-like activity in murine behavioral models. A simultaneous correlative neurochemical study was undertaken in postmortem hippocampal and striatal tissues for levels of vitamin C, the neurotransmitters, noradrenaline, serotonin and dopamine, as well as the metabolites 3, 4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and 5-hydroxyindole acetic acid (5-HIAA). Figure 1 Structure of the Gabapentin-fluoxetine derivative GBP1F. Female BALB/c mice (n=6/group) weighing 25–30g were acquired from the animal care facility of the Department of Pharmacy COMSATS University Islamabad, Abbottabad campus. The an -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal